Clinical trials: Recurrent Gallbladder Carcinoma
Gallbladder Cancer
Irinotecan in Treating Patients With Advanced Gallbladder or Bile Duct Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of irinotecan in treating patients with advanced…
- Trial name
- NCT00003276
- Testing
- irinotecan hydrochloride
- Where
- 21 sites in United States, Canada
- Volunteers
- 40 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Colorectal Cancer, Esophageal Cancer
Combination Chemotherapy in Treating Patients With Recurrent, Refractory, or Metastatic Solid Tumors or Lymphomas
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Colorectal Cancer, Esophageal Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer
- Trial name
- NCT00019513
- Testing
- fluorouracil, gemcitabine hydrochloride, leucovorin calcium
- Where
- United States
- Volunteers
- 108 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Extrahepatic Bile Duct Cancer, Gallbladder Cancer
Gemcitabine and Capecitabine in Treating Patients With Advanced and/or Inoperable Cholangiocarcinoma or Carcinoma of the Gallbladder
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and capecitabine, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00084942
- Testing
- capecitabine, gemcitabine hydrochloride
- Where
- United States
- Sponsor
- Roswell Park Cancer Institute
Adult Primary Cholangiocellular Carcinoma, Adult Primary Hepatocellular Carcinoma
BMS-247550 in Treating Patients With Liver or Gallbladder Cancer
Phase II trial to study the effectiveness of BMS-247550 in treating patients who have liver or gallbladder cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Adult Primary Cholangiocellular Carcinoma, Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Cholangiocarcinoma of the Extrahepatic Bile Duct
- Trial name
- NCT00023946
- Testing
- ixabepilone, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Cancer
Ondansetron With/Out Dexamethasone to Prevent Vomiting in Patients Receiving Radiation to the Upper Abdomen
RATIONALE: Antiemetic drugs may help to reduce or prevent vomiting in patients treated with radiation therapy. It is not yet known if ondansetron is more effective with or without dexamethasone in preventing vomiting caused by…
- Trial name
- NCT00016380
- Testing
- dexamethasone, ondansetron, quality-of-life assessment
- Where
- 14 sites in Canada
- Volunteers
- 211 people
- Sponsor
- NCIC Clinical Trials Group
Cancer
Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer
Phase I trial to study the effectiveness of trastuzumab plus R115777 in treating patients who have advanced or metastatic cancer.
- Trial name
- NCT00005842
- Testing
- trastuzumab, tipifarnib
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Biliary Tract Cancer, Cholangiocarcinoma
A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)
This is a multi-center, open-label, randomized, phase 2/3 trial of the bispecific antibody CTX-009 plus paclitaxel versus paclitaxel in patients with previously treated, unresectable advanced or metastatic biliary tract cancers.
- Conditions
- Biliary Tract Cancer, Cholangiocarcinoma, Gall Bladder Cancer, Ampullary Cancer
- Trial name
- NCT05506943
- Testing
- CTX-009, Paclitaxel
- Where
- 34 sites in United States
- Volunteers
- 168 people
- Sponsor
- Compass Therapeutics
Breast Cancer, Colorectal Cancer
Vaccine Therapy in Treating Patients With Advanced or Metastatic Cancer
RATIONALE: Vaccines made from a person's white blood cells that have been treated in the laboratory may make the body build an immune response to kill tumor cells.
- Conditions
- Breast Cancer, Colorectal Cancer, Gallbladder Cancer, Gastric Cancer
- Trial name
- NCT00027534
- Testing
- TRICOM-CEA(6D)
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Michael Morse, MD
Extrahepatic Bile Duct Cancer, Gallbladder Cancer
Oxaliplatin, Gemcitabine, Erlotinib, and Radiation Therapy in Treating Patients With Unresectable and/or Metastatic Pancreatic Cancer or Biliary Tract Cancer
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin and gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Pancreatic Cancer
- Trial name
- NCT00266097
- Testing
- erlotinib hydrochloride, gemcitabine hydrochloride, oxaliplatin
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Adult Primary Cholangiocellular Carcinoma, Advanced Adult Primary Liver Cancer
CPI-613 in Treating Patients With Advanced or Metastatic Bile Duct Cancer That Cannot Be Removed By Surgery
This pilot clinical trial studies 6,8-bis(benzylthio)octanoic acid in treating patients with advanced or metastatic cholangiocarcinoma that cannot be removed by surgery.
- Conditions
- Adult Primary Cholangiocellular Carcinoma, Advanced Adult Primary Liver Cancer, Cholangiocarcinoma of the Extrahepatic Bile Duct, Cholangiocarcinoma of the Gallbladder
- Trial name
- NCT01766219
- Testing
- 6,8-bis(benzylthio)octanoic acid
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Wake Forest University Health Sciences
Ampullary Cancer, Duodenal Cancer
Interventional Endoscopy Database for Pancreatico-biliary, Gastrointestinal and Esophageal Disorders
Our institution performs therapeutic ERCP (Endoscopic retrograde cholangiopancreatography ), Endoscopic Ultrasound (EUS) and Interventional Endoscopy in around 1000 patients a year.
- Conditions
- Ampullary Cancer, Duodenal Cancer, Bile Duct Cancer, Bile Duct Disorders
- Trial name
- NCT01438385
- Testing
- Interventional Endoscopy
- Where
- United States
- Volunteers
- 12,000 people
- Sponsor
- Weill Medical College of Cornell University
Cancer
MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma
RATIONALE: MS-275 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: This phase I trial is studying the side effects and best dose of MS-275 in treating patients with advanced solid…
- Trial name
- NCT00020579
- Testing
- entinostat
- Where
- 3 sites in United States
- Volunteers
- 75 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Extrahepatic Bile Duct Cancer, Gallbladder Cancer
Photodynamic Therapy in Treating Patients With Cancer of the Bile Duct, Gallbladder, or Pancreas
RATIONALE: Photodynamic therapy uses light and drugs that make cancer cells more sensitive to light to kill tumor cells. This may be effective treatment for cancer of the bile duct, gallbladder, or pancreas.
- Conditions
- Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer, Pancreatic Cancer
- Trial name
- NCT00003923
- Testing
- porfimer sodium
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Cholangiocarcinoma of the Extrahepatic Bile Duct, Cholangiocarcinoma of the Gallbladder
Stent Placement With or Without Photodynamic Therapy Using Porfimer Sodium as Palliative Treatment in Treating Patients With Stage III or Stage IV Cholangiocarcinoma That Cannot Be Removed By Surgery
RATIONALE: Stent placement may help reduce symptoms caused by the tumor. Photodynamic therapy uses a drug, such as porfimer sodium, that becomes active when it is exposed to a certain kind of light.
- Conditions
- Cholangiocarcinoma of the Extrahepatic Bile Duct, Cholangiocarcinoma of the Gallbladder, Unresectable Extrahepatic Bile Duct Cancer, Unresectable Gallbladder Cancer
- Trial name
- NCT00253617
- Testing
- porfimer sodium, adjuvant therapy, laser therapy
- Where
- 2 sites in United States, Canada
- Sponsor
- Jonsson Comprehensive Cancer Center
Cancer
Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer
RATIONALE: Learning about the relationship between platinum levels in the blood and neurotoxicity in patients receiving oxaliplatin may help plan treatment and may help patients live more comfortably.
- Trial name
- NCT00274885
- Testing
- oxaliplatin, management of therapy complications
- Where
- 6 sites in France
- Volunteers
- 58 people
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Extrahepatic Bile Duct Cancer, Gallbladder Cancer
Adjuvant Palliative Capecitabine and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Biliary Tract Cancer
RATIONALE: Drugs used in chemotherapy, such as capecitabine and gemcitabine, use different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer, Pain
- Trial name
- NCT00073905
- Testing
- capecitabine plus gemcitabine
- Where
- Switzerland
- Volunteers
- 44 people
- Sponsor
- Swiss Cancer Institute
Extrahepatic Bile Duct Adenocarcinoma, Gallbladder Adenocarcinoma
Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma
This phase II trial is studying how well giving sorafenib tosylate together with erlotinib hydrochloride works in treating patients with locally advanced, unresectable, or metastatic gallbladder cancer or cholangiocarcinoma.
- Conditions
- Extrahepatic Bile Duct Adenocarcinoma, Gallbladder Adenocarcinoma, Gallbladder Adenocarcinoma With Squamous Metaplasia, Hilar Cholangiocarcinoma
- Trial name
- NCT01093222
- Testing
- Erlotinib Hydrochloride, Sorafenib Tosylate
- Where
- 141 sites in United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix
7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)
This phase I trial is studying the side effects and best dose of giving 7-hydroxystaurosporine together with irinotecan hydrochloride in treating patients with metastatic or unresectable solid tumors, including triple-negative…
- Conditions
- Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix, Estrogen Receptor-negative Breast Cancer, Extensive Stage Small Cell Lung Cancer
- Trial name
- NCT00031681
- Testing
- 7-hydroxystaurosporine, irinotecan hydrochloride, diagnostic laboratory biomarker analysis
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Adult Primary Liver Cancer, Anaplastic Thyroid Cancer
Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu
Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill cancer cells.
- Conditions
- Advanced Adult Primary Liver Cancer, Anaplastic Thyroid Cancer, Bone Metastases, Carcinoma of the Appendix
- Trial name
- NCT00004074
- Testing
- recombinant interleukin-12, ABI-007/carboplatin/trastuzumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Biliary Tract Neoplasms, Recurrence
A Study of Capecitabine Versus S-1 as Adjuvant Therapy in Patients With Biliary Tract Carcinoma After Surgical Resection
The purpose of this study is to assess the difference of safety and efficacy about Capecitabine and S-1 for treatment of patients with low-risk of recurrence after BTC surgery.
- Conditions
- Biliary Tract Neoplasms, Recurrence, Cholangiocarcinoma, Gall Bladder Cancer
- Trial name
- NCT04856761
- Testing
- S-1, Capecitabine
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Fudan University